User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

Interactions with Platform & by Email *

INTERACTIONS

Unique # Participated *

PARTICIPANTS

Responses Validated *

VALIDATIONS

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   HPV Testing Market – Quick Facts.....II-11$100
   Global HPV Testing Market: A Prelude.....II-2
Current and Future Analysis.....II-2
1$100
   List of Select HPV Molecular Diagnostic Tests by Company and Technique.....II-31$100
   Cervical Cancer: Rising Incidence & Mortality Enhances Need for Testing.....II-41$100
   Major Risk Factors to HPV/Cervical Cancer.....II-5 1$100
   Table 1: Number of New Cervical Cancer Cases in the World by Region and Age Group (2012) (includes corresponding Graph/Chart).....II-6

Table 2: World Age-Standardized Cervical Cancer Incidence Rates (2012): Breakdown by Region (includes corresponding Graph/Chart).....II-6
1$350
   Table 3: Worldwide Cervical Cancer Mortality by Leading Countries (2012): Ranked by Number of Deaths (in ‘000s) (includes corresponding Graph/Chart).....II-7
HPV Testing for Primary Screening Indication Bodes Well for the Market’s
  Growth.....II-7
2$350
   Table 4: Cervical Screening Penetration in Select Countries (2012): % of Women in 20-69 Age Group Screened for Cervical Screening(includes corresponding Graph/Chart).....II-9
Developing Markets to Drive Global Growth.....II-9
1$350
   Table 5: Number of HPV Tests by Geographic Region (2012) (In Million) (includes corresponding Graph/Chart).....II-101$350
   Table 6: Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Normal Cytology (includes corresponding Graph/Chart).....II-11

Table 7: Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Cervical Cancer (includes corresponding Graph/Chart).....II-11
1$350
   Table 8: Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Low-Grade Lesions (includes corresponding Graph/Chart).....II-12

Table 9: Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with High-Grade Lesions (includes corresponding Graph/Chart).....II-12
1$350
   Latest Developments in HPV Testing Promise Bright Future Ahead.....II-13
Reimbursement Coverage Influences Adoption of HPV Testing.....II-13
1$100
   HPV Vaccination Programs: Assessing the Impact on HPV Testing Market.....II-141$100
   Some of the most common and rare side effects include:.....II-15
Gardasil - A Biohazard?.....II-15
Side-effects of Gardasil More Apparent among Preteens.....II-15
1$100
   Inhalable Cervical Cancer Vaccines to Grow in Popularity.....II-16
HPV Vaccine Proves Beneficial in Prevention of Genital Warts in Men.....II-16
HPV Vaccination Initiatives in Select Countries.....II-16
1$100
   HPV Vaccine Implementation: HPV Immunization Schedule and Population Coverage by
  Country.....II-17
2$200
   Qiagen, the Global Leader Face Headwinds from Roche.....II-19 1$100
   Table 10: Assessing the Impact of FDA’s Approval of Roche’s HPV Test on HPV Sales of Market Majors: Y-O-Y Quarterly HPV Sales Growth for QIAGEN, Hologic and Roche.....II-20

Table 11: Leading Players in the Global HPV Testing Market (2014E): Percentage Share Breakdown of Revenues for Abbott, Becton Dickinson, Hologic/Gen-probe, QIAGEN, Roche, and Others (includes corresponding Graph/Chart).....II-20
1$350
   Comparative Analysis of HPV Testing Products.....II-21
A Review of Select HPV Tests.....II-21
digene HC2 HPV DNA Test.....II-21
1$100
   digene HC2 High-Risk HPV DNA Test.....II-22
careHPV Test.....II-22
Cervista HPV HR Test.....II-22
1$100
   Cervista HPV 16/18 Test.....II-23
Cobas 4800 HPV test.....II-23
Aptima HPV Assay.....II-23
1$100
   HPV Testing: A Fast Growing Segment in the STD Diagnostic Testing Market.....II-24
Pap Cytology and HPV Co-testing: Improved Determination of Cervical Cancer
  Risk.....II-24
Cervical Cytology Screening: An Abstract.....II-24
1$100
   Conventional Pap Smear Tests Give Way to Liquid-based Cytology Tests.....II-25 1$100
   Table 12: Pap Tests Market in Select Countries (2014E): Percentage Share Breakdown of Number of Tests by Conventional Cytology Tests and Liquid-based Cytology Tests (includes corresponding Graph/Chart).....II-26

Table 13: Pap Smear Tests by Geography (2014E): Percentage Breakdown by Number of Tests for US, EU and Asia & Latin America (includes corresponding Graph/Chart).....II-26
Non-Invasive Urine HPV Test Holds Potential to Replace Pap Smear Test.....II-26
1$350
   Cervical Cancer Screening: Focus on Detection of CIN2 and CIN3 Cancers.....II-27
Regular HPV Screening Enhances Treatment and Survival Options.....II-27
Need for Genotyping of HPV Subtypes Beyond 16 & 18.....II-27
1$100
   Detecting E6 and E7 Oncoproteins to Improve Efficacy of Cervical Cancer
  Screening.....II-28
Novel Technological Developments to Enhance Accuracy of Screening Procedures.....II-28
1$100
   Use of Non-FDA Approved Tests for HPV Testing: A Major Concern.....II-291$100
   Increase in Instances of HPV-Linked Oral Cancer – A Cause of Deep Concern.....II-30
Research Findings Indicate Two Vaccination Doses Equal Three.....II-30
Men Found to be More Susceptible to Oral HPV Infections.....II-30
1$100
   Favorable Guidelines: A Key Growth Driving Factor.....II-31
Recommendations of Interim Guidance Report Issued by SGO and ASCCP: Jan 2015.....II-31
1$100
   Capitulation of Cervical Cancer Screening Guidelines (2009-2012).....II-321$100
   Revised Guidelines for Cervical Cancer Screening: 2012.....II-331$100
   HPV Test to be a Part of the New Cervical Cancer Screening Guidelines in the
  US.....II-34
US Government Proposes Administration of HPV Vaccine for Males.....II-34
1$100
   What is HPV?.....II-35
Types of HPV.....II-35
1$100
   Commonly Known Diseases and Related HPV Test Types.....II-36
Common Types of HPV Diseases.....II-36
Lung Cancer.....II-36
Cutaneous HPVs.....II-36
1$100
   Genital HPVs.....II-37
Throat Cancer.....II-37
Causes of Infection.....II-37
Cervical Cancer and HPV.....II-37
1$100
   HPV and Other Cancers.....II-38
Techniques for Detecting HPV.....II-38
Signal-Amplified Nucleic Acid Assays.....II-38
Target-Amplified HPV Assays.....II-38
What is HPV Testing?.....II-38
Test of HPV in Men.....II-38
1$100
   Test of HPV in Women.....II-39
HPV Test Results.....II-39
1$100
   Limitations of HPV Testing.....II-40
Advantages of HPV Testing.....II-40
Cervical Cytology Observation/Screening.....II-40
1$100
   Pap Smear Screening.....II-41
Requirements for Pap Smear Test.....II-41
1$100
   Advantages of Pap smear Test.....II-42
Limitations of Cytologic Screening.....II-42
HPV Testing vs. Cytology Testing.....II-42
1$100
   Abbott Introduces RealTime High Risk HPV Test.....II-43
Advanced Cell Diagnostics to Introduce HPV Assay Based on RNAscope Technology.....II-43
Roche Receives US FDA Approval for cobas HPV Test for First-Line Primary Screening
  for Cervical Cancer in Women.....II-43
Cepheid Releases Xpert® HPV Test for Cervical Cancer-Related HPV.....II-43
Qiagen Introduces careHPV™ Test in India.....II-43
BD Diagnostics Gains CE/IVD Marking for BD Onclarity™ HPV Assay.....II-43
Hologic Gains FDA Approval for Aptima HPV 16 18/45 Genotype Assay.....II-43
1$100
   QIAGEN Launches careHPV Test in China.....II-44
Roche Seeks Initial Screening Indication for Cobas HPV Test.....II-44
Hologic Secures Approval for Aptima HPV Assay from US FDA.....II-44
Cancer Genetics Introduces FHACT™ Test.....II-44
CureHealth Diagnostics Unveils New HPV Detection Technology in India.....II-44
Abbott Rolls Out RealTime High Risk HPV Test in Canada.....II-44
Trovagene Launches HPV-HR Test.....II-44
Hologic Bags FDA Approval for Using APTIMA HPV 16 18/45 Genotype Assay with TIGRIS
  System.....II-44
1$100
   FDA Grants Approval for Gen-Probe's PANTHER® System.....II-45
GenPath Women's Health Rolls Out GenCerv HPV Test.....II-45
Seegene Unveils QuantPlex HPV28 Genotyping Assay.....II-45
QIAGEN Launches QIAensemble Decapper Sample Preparation Automation System in
  Europe.....II-45
1$100
   Cancer Genetics Acquires BioServe India.....II-46
Arbor Vita Enters into Distribution Agreement with AB ANALITICA.....II-46
Australian MSAC Recommends HPV Testing as Primary Cervical Cancer Screening
  Tool.....II-46
CytoCore Announces Name Change to MEDITE Cancer Diagnostics.....II-46
Enzo Ties up with IncellDx Inc.....II-46
IncellDx Inks Agreement with GeneCell Diagnostics.....II-46
1$100
   IncellDx and Kindstar Global Ink Agreement.....II-47
Quest Diagnostics and Hologic Enter into Strategic Alliance.....II-47
QIAGEN and Calmette Hospital Enter into Partnership.....II-47
Hologic Acquires Gen-Probe.....II-47
QIAGEN Enters into Co-Marketing Agreement with KingMed Diagnostics.....II-47
Gynecor Implements cobas® 4800 Analyzer for HPV Test.....II-47
Molecular Pathology Laboratory Network to Adopt Hologic/Gen-Probe APTIMA HPV
  Assay.....II-47
Trovagene Inks Agreement with Strand Life Sciences.....II-47
1$100
   Bio-Reference Laboratories Acquires Stake in InCellDx.....II-48
QIAGEN Inks Co-Marketing Agreement with KingMed Diagnostics.....II-48
Roche Signs Agreement with Unilabs-IHS to Expand Access to HPV Testing in UK.....II-48
1$100
   Abbott Molecular, Inc. (US).....II-49
Arbor Vita Corporation (US).....II-49
1$100
   Becton, Dickinson and Company (US).....II-50
DaAn Gene Co., Ltd. (China).....II-50
1$100
   F. Hoffmann-La Roche Ltd. (Switzerland).....II-511$100
   Hologic, Inc. (US).....II-52
QIAGEN N.V. (The Netherlands).....II-52
1$100
   Seegene, Inc. (South Korea).....II-531$100
   Table 14: World Recent Past, Current and Future Analysis for HPV Testing by Geographic Region/ Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart).....II-541$350
   Table 15: World Historic Review for HPV Testing by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart).....II-551$350
   Table 16: World 12-Year Perspective for HPV Testing by Geographic Region/Country - Percentage Breakdown of Revenues for US, Japan, Europe, and Rest of World Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart).....II-561$350
   A. Market Analysis.....III-1
Cervical Cancer in the US – Key Statistics & Findings.....III-1
Table 17: Key Facts on Cervical Cancer in the US: 2014.....III-1
1$200
   Table 18: Prevalence of HPV in the US by Age (includes corresponding Graph/Chart).....III-2

Table 19: Prevalence of HPV16 and HPV18 in the US by Cytology (2014) (includes corresponding Graph/Chart).....III-2
1$200
   Table 20: Number of New Cervical Cancer Cases by US State (2015).....III-31$200
   Table 21: Incidence and Mortality Rate of Cervical Cancer by Ethnicity in the US (2007-2011) (includes corresponding Graph/Chart).....III-4
HPV Testing Market – A Review.....III-4
1$200
   Table 22: Cervical Cancer by HPV Type (2014E): Percentage Share Breakdown of Cervical Cancer Cases by HPV Type (includes corresponding Graph/Chart).....III-51$200
   Use of Non-FDA Approved Tests for HPV Testing: A Major Concern.....III-61$75
   Competitive Landscape.....III-7 1$75
   Table 23: Leading Players in the US HPV Testing Market (2013): Percentage Share Breakdown of Revenues for Hologic, QIAGEN, and Others (includes corresponding Graph/Chart).....III-8
Cytology Testing Market – An Insight.....III-8
Table 24: Pap Tests Market in the US (2014E): Percentage Share Breakdown of Number of Tests by Conventional Cytology Tests and Liquid-based Cytology Tests (includes corresponding Graph/Chart).....III-8
1$200
   HPV Vaccine Implementation.....III-9
Reimbursement of Screening Procedures.....III-9
Regulatory Landscape.....III-9
1$75
   Recommendations of Interim Guidance Report Issued by SGO and ASCCP: Jan
  2015.....III-10
Overview of Cervical Cancer Screening Guidelines.....III-10
2$150
   Revised Guidelines for Cervical Cancer Screening: 2012.....III-12
2011: US Government Proposes Administration of HPV Vaccine for Males.....III-12
1$75
   HPV Vaccine Implementation in the US Sates.....III-13
HPV Vaccines Legislations Passed by Individual US States (2011-2012).....III-13
1$75
   Product Introductions/Approvals.....III-141$75
   Strategic Corporate Developments.....III-151$75
   Key Players.....III-163$225
   B. Market Analytics.....III-19
Table 25: US Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-19
1$200
   Table 26: US Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart).....III-201$200
   A. Market Analysis.....III-21
Outlook.....III-21
Key Statistics in a Nutshell.....III-21
Table 27: Cervical Cancer in Japan (2014E): Percentage Share Breakdown of New Cases and Number of Deaths by Age Group (includes corresponding Graph/Chart).....III-21
1$200
   Table 28: Crude HPV Prevalence (%) in Women with Normal Cytology by Age Group (2014) (includes corresponding Graph/Chart).....III-22

Table 29: Japanese HPV Market (2012): Leading HPV Types Causing Cervical Cancer (includes corresponding Graph/Chart).....III-22
1$200
   Japan Discontinues Recommendation of FDA Approved HPV Drugs.....III-23
B. Market Analytics.....III-23
Table 30: Japanese Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-23
1$200
   Table 31: Japanese Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart).....III-241$200
   A. Market Analysis.....III-25
Outlook.....III-25
Cervical Cancer Screening in Europe – A Review.....III-25
1$75
   Table 32: Key Facts on Cervical Cancer in Europe: 2014 (includes corresponding Graph/Chart).....III-261$200
   Table 33: Estimated New Cervical Cancer Cases per Year in Europe by Region and Age Group: 2012 (includes corresponding Graph/Chart).....III-27

Table 34: Number of Deaths due to Cervical Cancer per Year in Europe by Region and Age Group: 2012 (includes corresponding Graph/Chart).....III-27
1$200
   Table 35: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Normal Cytology (includes corresponding Graph/Chart).....III-28

Table 36: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Low-Grade Lesions (includes corresponding Graph/Chart).....III-28
1$200
   Table 37: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with High-Grade Lesions (includes corresponding Graph/Chart).....III-29

Table 38: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Cervical Cancer (includes corresponding Graph/Chart).....III-29
1$200
   Table 39: Cervical Cancer Incidence and Mortality in European Countries (2012) (includes corresponding Graph/Chart).....III-301$200
   Table 40: Prevalence of Cervical Cancer in European Countries (2012) (includes corresponding Graph/Chart).....III-311$200
   Increasing Effectiveness of Cervical Cancer Screening Programs.....III-32
Need for Repeat Testing.....III-32
HPV – The Preferred Primary Screening for Cervical Cancer in Europe.....III-32
1$75
   Product Introductions/Approvals.....III-331$75
   B. Market Analytics.....III-34
Table 41: European Recent Past, Current and Future Analysis for HPV Testing by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-34
1$200
   Table 42: European Historic Review for HPV Testing by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart).....III-351$200
   Table 43: European 12-Year Perspective for HPV Testing by Geographic Region/Country - Percentage Breakdown of Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2009, 2015 and 2020 (includes corresponding Graph/Chart).....III-361$200
   A. Market Analysis.....III-37
Outlook.....III-37
Cervical Cancer in France – A Review.....III-37
Table 44: Key Facts on Cervical Cancer in France: 2014.....III-37

Table 45: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart).....III-37
1$200
   HPV Vaccine Implementation.....III-38
B. Market Analytics.....III-38
Table 46: French Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-38
1$200
   Table 47: French Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart).....III-391$200
   A. Market Analysis.....III-40
Outlook.....III-40
Cervical Cancer in Germany – A Review.....III-40
Table 48: Key Facts on Cervical Cancer in Germany: 2014.....III-40

Table 49: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart).....III-40
1$200
   B. Market Analytics.....III-41
Table 50: German Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-41
1$200
   Table 51: German Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart).....III-421$200
   A. Market Analysis.....III-43
Outlook.....III-43
Cervical Cancer in Italy – A Review.....III-43
Table 52: Key Facts on Cervical Cancer in Italy: 2014.....III-43

Table 53: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart).....III-43
1$200
   Strategic Corporate Development.....III-44
B. Market Analytics.....III-44
Table 54: Italian Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-44
1$200
   Table 55: Italian Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart).....III-451$200
   A. Market Analysis.....III-46
Market Overview.....III-46
Cervical Cancer – Key Statistics.....III-46
Table 56: Key Facts on Cervical Cancer in the UK: 2014.....III-46
1$200
   Table 57: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart).....III-47
Impact of HPV Vaccine Implementation.....III-47
1$200
   Strategic Corporate Development.....III-48
B. Market Analytics.....III-48
Table 58: UK Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-48
1$200
   Table 59: UK Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart).....III-491$200
   A. Market Analysis.....III-50
Outlook.....III-50
Spain.....III-50
Table 60: Cervical Cancer in Spain (2012): Percentage Share Breakdown of New Cases by Age-Group (includes corresponding Graph/Chart).....III-50

Table 61: Key Facts on Cervical Cancer in Spain: 2014.....III-50
1$200
   Table 62: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart).....III-51
Sweden.....III-51
Table 63: Key Facts on Cervical Cancer in Sweden: 2014.....III-51
1$200
   Table 64: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart).....III-52
The Netherlands.....III-52
Table 65: Key Facts on Cervical Cancer in the Netherlands: 2014.....III-52
1$200
   Table 66: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart).....III-53
Russia.....III-53
Table 67: Key Facts on Cervical Cancer in Russia: 2014.....III-53
1$200
   Table 68: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart).....III-54
Strategic Corporate Developments.....III-54
1$200
   Key Players.....III-552$150
   B. Market Analytics.....III-57
Table 69: Rest of Europe Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-57
1$200
   Table 70: Rest of Europe Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart).....III-581$200
   A. Market Analysis.....III-59
Outlook.....III-59
Focus on Select Markets.....III-59
Canada.....III-59
The Canadian Task Force on Preventive Health Care (CTFPHC) Recommendations
  for Cervical Cancer Screening: 2013.....III-59
1$75
   Table 71: Key Facts on Cervical Cancer in Canada: 2014.....III-60

Table 72: Estimated Age-Standardized Incidence Rates of Cervical Cancer per 100,000 Women Population in Canada by Province (2014) (includes corresponding Graph/Chart).....III-60
1$200
   Table 73: Estimated Age-Standardized Mortality Rates of Cervical Cancer per 100,000 Women Population in Canada by Province (2014) (includes corresponding Graph/Chart).....III-61

Table 74: Prevalence of HPV16 and HPV18 among Women in Canada by Cytology (2014) (includes corresponding Graph/Chart).....III-61
1$200
   Asia-Pacific.....III-62
Table 75: Key Facts on Cervical Cancer in Asia by Region: 2012 (includes corresponding Graph/Chart).....III-62
1$200
   Table 76: Incidence of Cervical Cancer in Asia by Region: 2012 (includes corresponding Graph/Chart).....III-63

Table 77: Estimated New Cervical Cancer Cases per Year in Asia by Region and Age Group: 2012 (includes corresponding Graph/Chart).....III-63
1$200
   Table 78: Number of Deaths due to Cervical Cancer per Year in Asia by Region and Age Group: 2012 (includes corresponding Graph/Chart).....III-64

Table 79: HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with Normal Cytology (includes corresponding Graph/Chart).....III-64
1$200
   Table 80: HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with Low-Grade Lesions (includes corresponding Graph/Chart).....III-65

Table 81: HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with High-Grade Lesions (includes corresponding Graph/Chart).....III-65

Table 82: HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with Cervical Cancer (includes corresponding Graph/Chart).....III-65
1$200
   China.....III-66
Introduction.....III-66
Table 83: Key Facts on Cervical Cancer in China: 2014.....III-66
1$200
   Table 84: Prevalence of HPV16 and HPV18 in China by Cytology (2014) (includes corresponding Graph/Chart).....III-67
New Testing Technologies Gain Traction.....III-67
Competitive Landscape.....III-67
1$200
   Table 85: Leading Players in China’s HPV Market (2012): Percentage Share Breakdown of Value for Digene, Kaipu, Yaneng, Mingyuan and Others (includes corresponding Graph/Chart).....III-68
India.....III-68
HPV Testing – A Nascent Market.....III-68
1$200
   TABLE 86: HPV Prevalence by Histology (includes corresponding Graph/Chart).....III-69
Table 87: Prevalence of HPV Types 16 and 18 among Women in India - Breakdown by Cytology (includes corresponding Graph/Chart).....III-69
1$200
   Table 88: Top 10 HPV Oncogenic Types among Women in India (2012): Breakdown of Prevalence (%) by Cytology.....III-701$200
   Table 89: Most Common HPV Oncogenic Types among Women with Invasive Cancer in India (2012): Breakdown of Prevalence (%) by Histology.....III-711$200
   Cervical Cancer Screening in India - Still a Long Way to Go.....III-72 1$75
   Table 90: Key Facts on Cervical Cancer in India: 2012.....III-73

Table 91: Cervical Cancer Incidence and Mortality in India: 2012.....III-73
1$200
   Table 92: Estimated New Cervical Cancer Cases Per Year by Age Group in India (As of 2012) (includes corresponding Graph/Chart).....III-74

Table 93: Number of Deaths due to Cervical Cancer per Year by Age Group in India (As of 2012) (includes corresponding Graph/Chart).....III-74
1$200
   Table 94: Crude Incidence Rate of Most Common Cancers among Women of all Ages in India: 2012 (includes corresponding Graph/Chart).....III-751$200
   Table 95: Crude Mortality Rate of Most Common Cancers among Women of all Ages in India: 2012 (includes corresponding Graph/Chart).....III-76
Australia.....III-76
1$200
   Table 96: Key Facts on Cervical Cancer in Australia: 2014.....III-77

Table 97: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart).....III-77
National Cervical Screening Program Continues to Taste Success.....III-77
1$200
   Cervarix® and Gardasil® to Combat Cervical Cancer.....III-78
New Zealand.....III-78
Table 98: Key Facts on Cervical Cancer in New Zealand: 2014.....III-78
1$200
   Table 99: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology.....III-79
Latin America.....III-79
Table 100: Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Normal Cytology (includes corresponding Graph/Chart).....III-79
1$200
   Table 101: Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Low-Grade Lesions (includes corresponding Graph/Chart).....III-80

Table 102: Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with High-Grade Lesions (includes corresponding Graph/Chart).....III-80
1$200
   Table 103: Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Cervical Cancer (includes corresponding Graph/Chart).....III-81
Brazil.....III-81
Table 104: Key Facts on Cervical Cancer in Brazil: 2014.....III-81
1$200
   Table 105: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart).....III-82
Mexico.....III-82
Table 106: Key Facts on Cervical Cancer in Mexico: 2014.....III-82
1$200
   Table 107: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart).....III-83
Africa.....III-83
Table 108: Key Facts on Cervical Cancer in Africa: 2014.....III-83
1$200
   Table 109: HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with Normal Cytology (includes corresponding Graph/Chart).....III-84

Table 110: HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with Low-Grade Lesions (includes corresponding Graph/Chart).....III-84
1$200
   Table 111: HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with High-Grade Lesions (includes corresponding Graph/Chart).....III-85

Table 112: HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with Cervical Cancer (includes corresponding Graph/Chart).....III-85
1$200
   Table 113: Cervical Cancer Incidence in Africa by Region: 2012 (includes corresponding Graph/Chart).....III-86

Table 114: Estimated New Cervical Cancer Cases per Year in Africa by Region and Age Group: 2012 (includes corresponding Graph/Chart).....III-86
1$200
   Table 115: Number of Deaths due to Cervical Cancer per Year in Africa by Region and Age Group: 2012 (includes corresponding Graph/Chart).....III-87

Table 116: Age-Standardized Cervical Cancer Incidence Rates in Africa by Region: 2012 (includes corresponding Graph/Chart).....III-87
1$200
   Table 117: Age-Standardized Cervical Cancer Mortality Rates in Africa by Region: 2012 (includes corresponding Graph/Chart).....III-88
Product Launches.....III-88
1$200
   Strategic Corporate Developments.....III-891$75
   Key Players.....III-901$75
   B. Market Analytics.....III-91
Table 118: Rest of World Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-91
1$200
   Table 119: Rest of World Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart).....III-921$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com